Enhancing Pediatric Adverse Drug Reaction Documentation in the Electronic Medical Record

dc.contributor.authorTillman, Emma M.
dc.contributor.authorSuppes, Sarah L.
dc.contributor.authorFeldman, Keith
dc.contributor.authorGoldman, Jennifer L.
dc.contributor.departmentPharmacology and Toxicology, School of Medicineen_US
dc.date.accessioned2022-02-21T18:52:38Z
dc.date.available2022-02-21T18:52:38Z
dc.date.issued2021-02
dc.description.abstractAdverse drug reactions (ADRs) often go unreported or are inaccurately documented in the electronic medical recorded (EMR), even when they are severe and life-threatening. Incomplete reporting can lead to future prescribing challenges and ADR reoccurrence. The aim of this study was to evaluate the documentation of ADRs within the EMR and determine specific factors associated with appropriate and timely ADR documentation. Retrospective data were collected from a pediatric hospital system ADR reports from October 2010 to November 2018. Data included implicated medication, type, and severity of reaction, treatment location, the presence or absence of ADR documentation in the EMR alert profile within 24 hours of the ADR hospital or clinic encounter discharge, ADR identification method, and the presence or absence of pharmacovigilance oversight at the facility where the ADR was treated. A linear regression model was applied to identify factors contributing to optimal ADR documentation. A total of 3065 ADRs requiring medical care were identified. Of these, 961 ADRs (31%) did not have appropriate documentation added to the EMR alert profile prior to discharge. ADRs were documented in the EMR 87% of the time with the presence of pharmacovigilance oversight and only 61% without prospective pharmacovigilance (P < .01). Severity of ADR was not a predictor of ADR documentation in the EMR, yet the implicated medication and location of treatment did impact reporting. An active pharmacovigilance service significantly improved pediatric ADR documentation. Further work is needed to assure timely, accurate ADR documentation.en_US
dc.eprint.versionAuthor's manuscripten_US
dc.identifier.citationTillman, E. M., Suppes, S. L., Feldman, K., & Goldman, J. L. (2021). Enhancing pediatric adverse drug reaction documentation in the electronic medical record. The Journal of Clinical Pharmacology, 61(2), 181-186. https://doi.org/10.1002/jcph.1717en_US
dc.identifier.urihttps://hdl.handle.net/1805/27892
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.isversionof10.1002/jcph.1717en_US
dc.relation.journalThe Journal of Clinical Pharmacologyen_US
dc.rightsPublisher Policyen_US
dc.sourceAuthoren_US
dc.subjectpediatricsen_US
dc.subjectpharmacovigilanceen_US
dc.subjectadverse drug reactionen_US
dc.titleEnhancing Pediatric Adverse Drug Reaction Documentation in the Electronic Medical Recorden_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Tillman_2021_enhancing.pdf
Size:
252.68 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: